Compare BRSP & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRSP | VOGX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 593.4M | 482.8M |
| IPO Year | 2017 | 2026 |
| Metric | BRSP | VOGX |
|---|---|---|
| Price | $4.20 | $28.92 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 142.6K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | ★ 75.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,587,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $14.80 |
| 52 Week High | $6.17 | $38.41 |
| Indicator | BRSP | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 21.69 | 58.99 |
| Support Level | N/A | $27.96 |
| Resistance Level | $5.75 | $35.06 |
| Average True Range (ATR) | 0.11 | 3.25 |
| MACD | -0.03 | -0.73 |
| Stochastic Oscillator | 17.42 | 2.00 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.